Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD8965 low dose
AZD8965 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo for AZD8965 | PLACEBO_COMPARATOR | Placebo for AZD8965 |
| AZD8965 low dose | EXPERIMENTAL | AZD8965 low dose |
| AZD8965 medium dose | EXPERIMENTAL | AZD8965 medium dose |
| AZD8965 high dose | EXPERIMENTAL | AZD8965 high dose |
| Name | Type | Description |
|---|---|---|
| Placebo for AZD8965 | OTHER | Placebo for AZD8965 |
| AZD8965 low dose | DRUG | AZD8965 low dose |
| AZD8965 medium dose | DRUG | AZD8965 medium dose |
| AZD8965 high dose | DRUG | AZD8965 high dose |
Inclusion Criteria: 1. Age ≥ 40 years 2. IPF diagnosis 3. Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care 4. FVC ≥ 45% predicted of normal 5. DLCO corrected for hemoglobin ≥ 25% predicted of norm...
Top 15 of 17 competitors
AZD8965 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN) for idiopathic pulmonary fibrosis, or IPF. It is currently in Phase 2 clinical development and has not been approved by the FDA. The program is being studied in a randomized, double-blind, placebo-controlled trial.
AZD8965 is being evaluated as a treatment for idiopathic pulmonary fibrosis (IPF), a chronic respiratory condition. It is an investigational therapy in Phase 2 development and is not approved for any indication. The ongoing study enrolls adults aged 40 years and older with IPF across multiple countries.
AZD8965 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is running the Phase 2b clinical program for the drug in idiopathic pulmonary fibrosis. The asset is an investigational small molecule and remains in clinical development.
AZD8965 is in Phase 2 development. The ongoing trial is a Phase 2b study in participants with idiopathic pulmonary fibrosis. AZD8965 is investigational and has not received FDA approval. No completed trials of AZD8965 have been reported.
AZD8965 is being studied in one active clinical trial, NCT07652658, titled A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. The trial is currently recruiting and plans to enroll 359 participants. It is randomized, double-blind, and placebo-controlled, and is conducted across the United States, Europe, Asia, and other regions.
AZD8965 low dose is an alternative name used for AZD8965, the investigational small molecule developed by AstraZeneca PLC for idiopathic pulmonary fibrosis. Both names refer to the same Phase 2 asset. The ongoing Phase 2b trial, NCT07652658, is evaluating AZD8965 in participants with IPF.